Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian … (NCT01955382) | Clinical Trial Compass
CompletedPhase 2
Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
Mali70 participantsStarted 2013-09
Plain-language summary
Background:
\- Malaria is caused by small parasites carried by some mosquitoes. People can get malaria if an infected mosquito bites them. Malaria destroys red blood cells. Most malaria is mild, but some children develop severe malaria, which kills about 660,000 people annually. About 9 in 10 who die of malaria are Sub-Saharan African children, most under 5 years old. Scientists can save many lives if they find out how to prevent or relieve severe malaria.
Objective:
\- To know if a common medicine called activated charcoal can reduce severe malaria symptoms.
Eligibility:
\- Children 2 to 11 years old with mild malaria who live in Kenieroba, Mali.
Design:
* For the first 2 days and nights, participants will stay in the hospital.
* They will have their medical history taken, and a physical exam.
* Blood will be drawn from a thin tube inserted in their hand or forearm. This will be done 3 times overall. A drop of blood will be taken from a finger prick 12 times overall.
* An antimalarial drug will be injected into the tube in the arm 4 times. Each time the drug is given, participants will drink a small cup of either water or activated charcoal.
* For the following 3 days, participants will take an antimalarial pill.
* On day 7, participants will visit the hospital. A drop of blood from a finger prick will be tested for malaria parasites.
Who can participate
Age range2 Years – 10 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 2 to 10 years, inclusive
✓. Resident of Kenieroba
✓. Uncomplicated malaria\*
✓. P. falciparum density 10,000 70,000/micro L, inclusive
✓. Willingness to participate in the study as evidenced by informed consent of the child s parent or guardian
✓. Ability to swallow oral medication
Exclusion criteria
✕. Severe malaria
✕. Any medical condition or history, including allergy to AS, AQ, artemether or lumefantrine, that poses a risk to the prospective participant
✕. Any condition that in the opinion of the investigator would render the participant unable to comply with the protocol (e.g., psychiatric disease)
✕. Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary risks to study participants (e.g., severe malnutrition, acquired or inherited immunodeficiency)
What they're measuring
1
Parasite Clearance Half-life
Timeframe: During patient treatment
2
Safety
Timeframe: During patient treatment up to 48 hours
Trial details
NCT IDNCT01955382
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)